♦ Background: As an immune system regulator, vitamin D is commonly deficient among patients on peritoneal dialysis (PD), which may contribute to their impaired immune function and increased risk for PD-related peritonitis. In this study, we aimed to investigate whether vitamin D deficiency could predict the risk of peritonitis in a prospective cohort of patients on PD. 
T he nonclassical effects of vitamin D on the immune system, cardiovascular disease, and cancer, unrelated to its effects on bone metabolism, have been broadly investigated in recent years. Among these, the immunomodulating actions of vitamin D have received considerable attention. Vitamin D signaling pathways regulate both innate and adaptive immunity, thereby maintaining the associated inflammatory response within physiological limits (1, 2) . Vitamin D deficiency contributes to microinflammation and a defective immune system, which are associated with a variety of infectious diseases. During the past few years, the link between vitamin D deficiency and infection susceptibility has been investigated in the general population (3) (4) (5) .
The prevalence of vitamin D deficiency evaluated by serum 25-hydroxyvitamin D (25[OH]D) levels was found to be substantially high, ranging from 50% to 98% in the dialysis population (6) (7) (8) (9) . It is also well established that patients on dialysis suffer from an impaired immune system and are highly susceptible to infections compared to the general population (10) . For patients on peritoneal dialysis (PD), peritonitis is the most common infectious complication, contributing to treatment failure, hospitalization, and death. Whether vitamin D deficiency contributes to the increased risk for PD-related peritonitis and poor outcome is uncertain. To date, evidence concerning this theory is limited, with only 2 retrospective studies having shown a positive association between oral active vitamin D therapy and the decreased risk for peritonitis (11, 12) . Both studies, however, failed to report serum 25(OH)D levels for either the intervention or control groups, leaving uncertainty about the association between vitamin D deficiency and peritonitis risk in each case.
Therefore, we aimed to determine whether serum 25(OH) D levels could predict the occurrence of peritonitis in a large cohort of PD patients from 2 PD units. Of note, the external active vitamin D supplementation, comorbidity load, and nutritional status may be potential confounders for the association of serum 25(OH)D and peritonitis risk. And, individuals with vitamin D deficiency are prone to be weak and malnourished (13) . Therefore, active vitamin D supplementation, comorbidity load, nutritional status, and physical performance would need to be taken into account in determining the above link. Basic demographic data, including age, gender, body weight, height, duration of PD, comorbidities, and the presence of peritonitis history, were collected at baseline. The Charlson index was used to assess the comorbidity load. Physical performance was assessed using the Karnofsky index (14) . All laboratory samples except for serum 25(OH)D were analyzed by standard laboratory techniques in the local hospitals including hemoglobin (Hb), serum albumin (ALB), calcium, phosphate, intact parathyroid hormone (iPTH), and high sensitive C-reactive protein (hs-CRP). Dialysis adequacy and residual renal function (RRF) were also measured. Dialysis adequacy was defined as weekly total Kt/V (TKt/V) and total creatinine clearance (Tccr). Residual renal function was defined as the mean of residual creatinine clearance and residual urea clearance. The normalized protein equivalent of total nitrogen appearance (nPNA) was calculated using the Bergstrom for mula (15) . Serum iPTH was measured by the chemiluminescence assay (reference range: 15 ~ 65 pg/mL). Serum hs-CRP was measured by immune rate nephelometric analysis.
SERUM 25(OH)D MEASUREMENTS AND ORAL VITAMIN D SUPPLEMENTS
Extra serum samples were obtained at baseline and then at 6-month intervals during follow-up. Samples were centrifuged at 3,000 rpm for 10 minutes, and then stored at -80ºC until analysis for 25(OH)D. Baseline serum 25(OH)D was measured for each subject. For subjects that developed peritonitis, frozen samples at the nearest time point prior to peritonitis onset were examined for serum 25(OH)D. For subjects who experienced more than 1 episode of peritonitis during the follow-up period, we measured serum 25(OH)D prior to their first episode only. Serum 25(OH)D was measured by enzyme-linked immunosorbent assay (ELISA, Immunodiagnostic Systems Ltd, Bolden, UK) in Peking University First Hospital. The ELISA kit we used can not cross react with 1,25(OH)2D.
During the study period, medication regimens and oral active vitamin D (calcitriol or alfacalcidol) supplements for each patient were recorded at 1-month intervals and mean weekly doses were then calculated. Alfacalcidol doses were converted to the calcitriol equivalent by multiplying by 0.75 (16) .
DIAGNOSIS OF PERITONITIS
The outcome was defined as the occurrence of peritonitis during follow-up. Peritonitis was defined as the presence of at least 2 of the following conditions: (1) abdominal pain or tenderness, (2) presence of white blood cells (100 cells/mL) in peritoneal effluent, with at least 50% polymorphs, and (3) positive dialysate culture results. In cases where abdominal pain or tenderness were unavailable, cloudy fluid combined with at least 1 of the latter 2 conditions were considered diagnostic (17) .
Examination of effluent included cell counts, causative micro-organisms, and drug sensitivities. For each episode of peritonitis, we recorded the initial effluent white blood cell count (day 0) and then the serial white blood cell counts on scheduled follow-up visits on days 1, 3, 5, 7, and 14. The disease severity score (DSS) (range: 0 -5 points) was calculated as the sum of points for pain and fever (18) .
TREATMENT FOR PERITONITIS
Peritonitis was treated with the standard antibiotic protocol, modified from the International Society for Peritoneal Dialysis (ISPD) guidelines (19) . In general, initial antimicrobial therapy for peritonitis consisted of intra-peritoneal administration of a third generation cephalosporin plus cefazolin (both with a single dose of 1 g once daily). Antibiotic treatment was modified once the culture results and antimicrobial sensitivities became available. Patients were switched to hemodialysis and their PD catheters were subsequently removed if they showed a lack of improvement after 7-14 days of appropriate antibiotic therapy, if PD dialysate grew yeast species or tuberculosis at any time, and if a clinical tunnel infection was diagnosed at the start as suggested by the ISPD guidelines (19) . Subjects were divided by baseline or pre-peritonitis serum 25(OH)D levels. Differences were compared using the analysis of variance (ANOVA), Fisher's exact test, chi-squared test, and Kruskal-Wallis H test between 3 groups, as appropriate, or by using the unpaired Student's t-test, Mann-Whitney U test, and chi-squared test between 2 groups, as appropriate.
We aimed to determine the prognostic value of baseline 25(OH)D for the incidence of peritonitis. Multivariate Cox regression models were built to determine this association, adjusting for: (1) The predictive role of baseline 25(OH)D for the occurrence of peritonitis was examined in multivariate Cox regression models. After adjustment for age, gender, dialysis duration, DM, ALB, RRF, and history of peritonitis, baseline 25(OH) D (1 nmol/L) as a continuous variable was an independent predictor of peritonitis (HR = 0.94; 95% CI 0.90 -0.98). When patients were tertiled by baseline serum 25(OH)D, Kaplan-Meier analysis showed that time-to-peritonitis episode was significantly shorter for patients in the low tertile compared to patients in the high tertile group (p = 0.003, Figure 2 ). In addition, baseline 25(OH)D as a categorical variable was used in multivariate Cox regression models. As shown in Table 2 Table 3 , there were no significant differences in DSS and dialysate white cell counts on days 0, 3, and 5, or with respect to the distribution of the causative organism between episodes dichotomized by the median pre-peritonitis 25(OH)D level. However, patients in the low pre-peritonitis 25(OH)D group tended to experience subsequent peritonitis during follow-up compared to those in the high group (p = 0.04).
DISCUSSION
This study indicated that vitamin D deficiency was prone to be prevalent in diabetic PD patients with long duration on dialysis, accompanied by malnutrition and inflammation. The vitamin D status evaluated via serum 25(OH)D level could predict the occurrence of peritonitis in this prospective PD (21) . Second, the expression of cathelicidin, an antimicrobial peptide with broad spectrum activity, can be upregulated by vitamin D in a wide range of human cells (20) . Third, microinflammation is associated with immune dysfunction for patients with chronic kidney disease (10) , and vitamin D contributes to maintaining inflammatory response within physiological limits (1).
Of note, in our study, the prognostic value of 25(OH)D was independent of oral calcitriol (1, 25 [OH] 2 D) or alfacalcidol (precursor of 1,25[OH] 2 D). This phenomenon may be explained by the fact that the ability of vitamin D to influence human immune responsiveness seems to be highly dependent on 25(OH)D status, the main circulating vitamin D metabolite (5) . Calcitriol and alfacalcidol were thought to be exclusively active for calcium homeostasis in patients with chronic kidney disease, as the characteristic short half-life for active vitamin D forms does not exert an immunomodulating action on many extrarenal cells. To the contrary, cholecalciferol supplementation could increase serum 25(OH) obviously, alter calcitriol-responsive monocyte proteins, and decrease inflammatory cytokines during hemodialysis (22) . Therefore, it is recommended that native vitamin D should be combined with active vitamin D supplements in patients with chronic kidney disease (23) .
We are aware that patients in the low 25(OH)D tertile group appeared to be "sicker" than those in the middle and high groups. So we added Charlson index and Karnofsky index into the Cox regression model, and baseline 25(OH)D was still an independent predictor of peritonitis. These findings indicated that the link between vitamin D deficiency and susceptibility to infection could not be totally explained by malnutrition and frailty. However, we also recognized that the weakness of patients could not be assessed by Charlson index and Karnofsky index comprehensively. Accordingly, the confounding effect of general frailty is not excluded. Future studies need to be performed to (24); we could not use 50 nmol/L as a cut-off point in our study because only 3 patients had baseline serum 25(OH)D levels higher than this. The serum 25(OH)D levels in this study are also lower than their hemodialysis counterparts as reported previously (25, 26) , but comparable to PD patients (8) . Since the benefits of external vitamin D supplementation in modulating immune function is based on improving vitamin D status, the therapeutic regimen for vitamin D repletion should be explored in terms of improving the vitamin D status of the host-that is, an increase in serum 25(OH)D levels. Unfortunately, vitamin D replacement strategies applied in present clinical trials vary in frequency and dose for treating infection (4) . A variable regime for cholecalciferol (10,333 IU weekly -100,000 IU monthly) has also been confirmed to be effective and safe with good compliance for hemodialysis patients (27) (28) (29) . We hope that more studies will be performed to explore the association between prescribed vitamin D dose and the 25(OH)D level achieved.
This study has some distinct advantages over previous studies. First, a series of serum samples were collected at baseline and then at 6-month intervals. This provided a unique chance to explore the association between baseline/pre-peritonitis serum vitamin D status and peritonitis risk. Second, oral vitamin D supplements as a critical confounder were recorded prospectively during the study period, thereby avoiding recall bias induced by retrospective data collection. Third, other recognized confounders were also taken into account simultaneously when determining the association between 25(OH)D and peritonitis risk. The relatively large sample size and prospective design are also merits of this study.
However, the present study is not without limitations. For instance, as an observational study, a cause-effect relationship could not be established. Furthermore, the potential mechanisms for the immunomodulating effect of serum vitamin D status on peritonitis risk are not clear. Measurements of innate and acquired immune dysfunction related to vitamin D deficiency would be helpful to address this issue. Also, there is a possibility of selection bias since 30% of prevalent PD patients were not included in this study. Since the peritonitis rate and the spectrum of pathogenic bacteria in the present study are comparable to our previous studies (17, 30) , subjects of this study can be considered representative. In addition, the study period was relatively short and the frequency of peritonitis was low. If the observation period is lengthened and more outcome events recorded, more statistical power to solidify our main findings would be realized.
In conclusion, vitamin D deficiency evaluated by serum 25(OH)D levels rather than active vitamin D supplementation at the present doses contributes to a higher risk of peritonitis. Clinicians and researchers should explore the potential immunological actions of vitamin D and its contribution to peritonitis in the PD population. More studies are needed to determine the effect of oral vitamin D supplements on decreasing peritonitis rates and attaining target vitamin D repletion.
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